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OBJECTIVE — Toestimatemedicalexpendituresattributabletodiabetesketoacidosis(DKA)
and severe hypoglycemia among privately insured insulin-treated U.S. youth with diabetes.
RESEARCH DESIGN AND METHODS — We analyzed the insurance claims of 7,556
youth, age 19 years, with insulin-treated diabetes. The youth were continuously enrolled in
fee-for-service health plans, and claims were obtained from the 2007 U.S. MarketScan Com-
mercial Claims and Encounter database. We used regression models to estimate total medical
expenditures and their subcomponents: outpatient, inpatient, and drug expenditures. The ex-
cessexpendituresassociatedwithDKAandseverehypoglycemiawereestimatedasthedifference
between predicted medical expenditures for youth who did/did not experience either DKA or
severe hypoglycemia.
RESULTS — For youth with and without DKA, respectively, predicted mean annual total
medical expenditures were $14,236 and $8,398 (an excess of $5,837 for those with DKA). The
excess was statistically greater for those with one or more episodes of DKA ($8,455) than among
those with only one episode ($3,554). Predicted mean annual total medical expenditures were
$12,850 and $8,970 for youth with and without severe hypoglycemia, respectively (an excess of
$3,880 for those with severe hypoglycemia). The excess was greater among those with one or
more episodes ($5,929) than among those with only one ($2,888).
CONCLUSIONS — Medical expenditures for potentially preventable DKA and severe hy-
poglycemia in U.S. youth with insulin-treated diabetes are substantial. Improving the quality of
care for these youth to prevent the development of these two complications could avert sub-
stantial U.S. health care expenditures.
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D
iabetes ketoacidosis (DKA) and se-
vere hypoglycemia are two com-
mon acute diabetes complications
in youth. DKA, which results from abso-
lute or relative insulin deﬁciency, can be
the initial clinical presentation of both
type 1 and type 2 diabetes or can occur in
those with an established diabetes diag-
nosis. Severe hypoglycemia is a serious
side effect of insulin treatment, especially
for children and adolescents with type 1
diabetes. Despite substantial progress in
diabetes management and care over the
last 20 years (1), incidence and preva-
lence of these potentially preventable
complications remain high (2,5). In
2006, among people in the U.S. with di-
abetes aged 0–17 years, 64% of the ﬁrst-
listed hospital discharge diagnoses
included DKA (http://www.cdc.gov/
diabetes/statistics/hosp/kidtable1.htm, ac-
cessed on 26 April 2010). An estimated
15–29% of youth with diabetes had DKA
at the onset of diabetes (4–7). Among
those aged 19 years with established
type 1 diabetes, the overall incidence of
DKA and severe hypoglycemia was esti-
mated to be 8 and 19 per 100 patient-
years, respectively (2).
In addition to the risk for premature
death and lower quality of life associated
with these conditions, both DKA and se-
vere hypoglycemia impose large eco-
nomic burdens on the health care system
(2,3,8,9). Medical expenses attributed to
DKA and severe hypoglycemia have been
estimated in diabetic adults (9–13), but
similar estimates are not available for U.S.
youth (age 20 years). We are aware of
no studies that examine excess medical
expenditures in youth experiencing re-
current DKA or severe hypoglycemia
episodes.
To evaluate the economic efﬁciency
of programs aimed at improving quality
of care and to establish health care poli-
cies for youth with diabetes, estimates of
excess medical expenditures associated
with these acute complications are
needed.Thus,ourstudy’sobjectiveswere
to 1) estimate the excess medical expen-
ditures associated with DKA and severe
hypoglycemia among youth with insulin-
treated diabetes (ITDM) and 2) to exam-
ine the extent to which the excess
expenditures are associated with the
number of episodes of these
complications.
RESEARCH DESIGN AND
METHODS
Data source
We used the 2007 MarketScan Commer-
cial Claims and Encounters (CCE) Data-
base (MarketScan Database; Thompson
Medstat, Ann Arbor, MI). This database,
which has been used extensively in stud-
ies of health care costs, including studies
of diabetes costs (12,14–16), contains
fully adjudicated and paid claims for sev-
eral million people with employer-
sponsored health plans, including
employees, spouses, and dependents
(17). The CCE database includes patient-
level data on inpatient, outpatient, and
drug claims that can be linked using en-
crypted enrollee information. Types of
health plans from which enrollees obtain
services can be divided into fee-for-
service (FFS) plans and fully or partially
capitated plans. FFS plans include pre-
ferredproviderorganization(PPO)plans,
exclusive provider organization plans,
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, Georgia.
Corresponding author: Sundar S. Shrestha, sshrestha@cdc.gov.
Received 22 July 2010 and accepted 7 September 2010. Published ahead of print at http://care.
diabetesjournals.org on 15 September 2010. DOI: 10.2337/dc10-1406.
The ﬁndings and conclusions in this report are those of the authors and do not necessarily represent the
ofﬁcial position of the Centers for Disease Control and Prevention.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Epidemiology/Health Services Research
ORIGINAL ARTICLE
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 2617point-of-service (POS) plans, consumer-
directed health plans, and indemnity
plans. Fully or partially capitated plans
include HMO plans and capitated POS
plans (18). Cost estimation for those en-
rolled in FFS health plans is straightfor-
ward, because claims represent the
payments for each service. For those en-
rolledincapitatedplans,paymentrecords
often reﬂect encounter status and not the
actual payment (18). Therefore, we lim-
itedouranalysistoyouthinFFSplans.All
expenses are in 2007 U.S. dollars.
Study population
Our study population consisted of U.S.
youth who had health care service and
prescription drug coverage through an
FFS plan between 1 January and 30 De-
cember 2007.
Identiﬁcation of youth with DKA
and severe hypoglycemia
Youth with DKA and severe hypoglyce-
mia were identiﬁed in three steps. First,
followingcriteriausedinapreviousstudy
(19), enrollees were identiﬁed as having
diabetesifduringcalendaryear2007they
had at least one claim for diabetes-related
drugs and supplies and at least two out-
patient encounters 30 days apart in
which diabetes was a primary or second-
ary diagnosis or at least one inpatient ad-
mission with diabetes as a primary or
secondary diagnosis. The requirement of
at least two outpatient encounters ex-
cludes those who were misdiagnosed at
the ﬁrst encounter but later determined
not to have diabetes (16). We used the
ICD-9-CM codes 250.00–250.93, 357.2,
362.0–362.02,and366.41(18)asdiabe-
tes indicators in the outpatient and inpa-
tient claims. In the second step, youth
with DM were identiﬁed to have ITDM if
they had at least one drug claim for insu-
lin as indicated by therapeutic class code
172. Last, youth with ITDM were identi-
ﬁed to have DKA if they had any claims
coded with ICD-9-CM code 250.1 (2)
and with severe hypoglycemia if they had
any claims coded with ICD-9-CM codes
251.0, 251.1, 251.2, or 250.8 (12).
To determine the extent to which the
number of episodes of DKA or severe hy-
poglycemia was associated with excess
expenditures, we dichotomized youth
with these complications into those hav-
ing one episode and those having more
than one episode. We considered an indi-
vidual to have had one episode of DKA if
theyreceivedoneservicewithaDKAcode
during the study period and to have had
more than one episode if they had re-
ceivedatleasttwosuchservicesatleast30
daysapart.Weusedthesameapproachto
determine the number of severe hypogly-
cemia episodes.
Complete records were available for
7,724 youth with ITDM. We excluded 39
with missing census region or urbanity of
residence (urban versus rural). We also
excluded 129 people with uncommon
chronic conditions (congenital heart fail-
ure, hemiplegia, lymphoma, Down’s syn-
drome, autism, leukemia, liver diseases,
and congenital heart defects). We could
notconsidertheseconditionsbecausethe
number of youth experiencing each con-
dition was very small (e.g., 10 among
DKA or severe hypoglycemia youth).
Thus, our ﬁnal analytic database had
7,556 youth. Because of its relative high
prevalence and possible interaction with
diabetesexpenditures,wedidnotexclude
309 (4.1%) youth with asthma.
Statistical analyses
WeusedStataversion10.1(Stata,College
Station,TX)forallanalyses.Weestimated
four expenditure models (outpatient, in-
patient, drug, and total). The presence or
absence of DKA or severe hypoglycemia
were modeled using two indicator vari-
ables in each of the four models. Covari-
ates included age, sex, census region
(midwest, south, west, and northeast),
residence urbanity, health beneﬁt plan
type (PPO versus non-PPO), and pres-
enceofasthma.Wealsoestimatedmodels
including the DKA/severe hypoglycemia
interaction term.
We compared the unadjusted means
of the characteristics of youth by their
DKA or severe hypoglycemia status with
Student t tests. We used a generalized lin-
ear model with log link and gamma dis-
tribution to model total, outpatient, and
drug expenditures because all youth had
positive expenditures and expenditures
were highly skewed and right tailed (20).
Weusedatwo-partmodeltomodelinpa-
tient expenditures to account for those
with no inpatient expenditures (21,22).
In the ﬁrst part of the two-part model, we
used logistic regression to estimate the
probability that someone would have
had any inpatient expenditures, and, in
the second part, we used a generalized
linear model with log link and gamma
distribution to estimate the inpatient
expenditures for those who had such
expenditures.
Wecalculatedmodel-basedpredicted
marginal medical expenditures by DKA
status. In this approach, predictions were
made for all observations assuming no
DKA status for all observations and then
again assuming DKA. All other variables
remainedattheiroriginalvalues.Thepre-
dictedexcessexpenditureassociatedwith
DKA was calculated as the difference be-
tween the predicted expenditures for
youth with and without DKA. We used
thesameapproachtoestimatemeanmed-
ical expenditures for youth by severe hy-
poglycemia status and predicted excess
expenditure associated with severe hypo-
glycemia. We used 100 nonparametric
bootstrap replications to calculate the es-
timates’ standard errors. We considered
results signiﬁcant if P  0.05.
RESULTS— Of 7,556 youth with
ITDM, 1,126 (14.9%) experienced at
least one DKA episode. Of those, 600
(53.3%) experienced one episode and
526 (46.7%) experienced more than one
(mean 2.6). Of all youth with ITDM, 595
(7.9%)experiencedatleastoneseverehy-
poglycemic episode. Of those, 400
(67.2%) had one episode and 195
(32.8%) had more than one (mean 3.5).
The study population characteristics
byDKAorseverehypoglycemiastatusap-
pear in Table 1. The mean age was 13
years, and those who experienced DKA
were signiﬁcantly younger than those
who did not (P  0.05). The proportion
of girls was signiﬁcantly greater among
those with DKA or severe hypoglycemia
than among those with neither (P 
0.05). Those with DKA were more likely
to reside in the south but less likely to
reside in the midwest region; those with
severe hypoglycemia were less likely to
reside in the west (P  0.05). About four-
ﬁfths of the youth, regardless of DKA or
severe hypoglycemia status, lived in ur-
ban areas. Asthma was signiﬁcantly more
prevalent among youth who had DKA or
severe hypoglycemia than among those
with neither (P  0.05).
Unadjusted mean medical
expenditures
Unadjusted total mean medical expen-
ditures were $6,191 more for youth
with at least one DKA episode than for
those with none and $5,151 more for
those with at least one severe hypogly-
cemia episode than for those with none
(P  0.05) (Table 2). Except for drug
expenditures by severe hypoglycemia
status, the unadjusted means for all ex-
penditure categories were also signiﬁ-
cantly greater among youth with DKA
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thosewithout(P0.05).Atotalof83%
of the youth in our sample had zero in-
patient expenditures (Table 2).
Factors associated with medical
expenditures
Total medical expenditures were signiﬁ-
cantly less among youth residing in the
midwest and south than in those residing
in the northeast (P  0.05) (Table 3). Ex-
penditures were signiﬁcantly greater
among youth with asthma, DKA, or se-
vere hypoglycemia compared with their
counterparts (P  0.05). Outpatient ex-
penditure was greater among girls than
among boys (P  0.05). Those in the
south and west had signiﬁcantly lower
outpatient expenditures than those in the
northeast (P  0.05). Outpatient expen-
ditures were signiﬁcantly greater among
youth with asthma, DKA, or severe hypo-
glycemia than among their counterparts
(P  0.05). The probability of having in-
patient expenditures decreased with age;
however, the expenditure increased with
age(P0.05).Thoseresidinginthemid-
west and south were signiﬁcantly less
likely to be admitted to the hospital than
those in the northeast (P  0.05). Both
probability of having inpatient expendi-
ture and expenditures were greater
among youth with asthma than those
without and greater among those with at
least one severe hypoglycemia episode
than among those with none (P  0.05).
Those with DKA were signiﬁcantly more
likely than those without to be admitted
to the hospital (P  0.05). Prescription
drug expenditures decreased with age
andweregreateramongboysthanamong
girls (P  0.05). Residents of other re-
gions had signiﬁcantly less prescription
drug expenditures than northeastern res-
idents (P  0.05). Prescription drugs ex-
penditures were greater in urban areas
than in rural areas, greater among youth
with asthma than those without, and
greater among those with at least one se-
vere hypoglycemia episode than among
those with none but signiﬁcantly lower
among those with DKA than those with-
out DKA (P  0.05). The terms for the
DKA/severe hypoglycemia interaction
were not signiﬁcant and therefore ex-
cluded in all the analyses.
Medical expenditures associated
with DKA
The predicted mean total medical expen-
diture was $8,398 for youth with no DKA
episodes and $5,837 more for those who
had at least one (P  0.05). Mean outpa-
tient and inpatient expenditures were sig-
niﬁcantly greater among youth who had
at least one DKA episode (P  0.05) (Ta-
ble 4). Inpatient expenditures accounted
for slightly 40% of the total medical ex-
penditures incurred by youth who had
DKA, but excess inpatient expenditures
were 90% of the excess expenditure at-
tributable to DKA. In contrast, mean pre-
scription drug costs were lower among
youth who had DKA than those who did
not (P  0.05). The mean excess total
medical expenditure for youth who had
one episode of DKA was $3,554, which
wasabouthalfthanthatofyouthwhohad
more than one ($8,455). Excess inpatient
expenditures accounted for 90% of the
excess medical expenditures associated
with both one and more than one episode
of DKA. The mean annual total medical
expenditure for those who had DKA was
1.7 times greater than for those without
and was even greater for those with mul-
tiple DKA episodes.
Medical expenditures associated
with severe hypoglycemia
The predicted mean total medical expen-
diture was $8,970 for ITDM youth who
had no severe hypoglycemia and $3,880
moreforthosewhohadatleastonesevere
hypoglycemia(P0.05)(Table4).Com-
pared with youth who had no severe hy-
poglycemia episodes, the mean excess
total medical expenditure was $2,888
among those who had one episode and
$5,929 among those who had more than
one episode. Excess outpatient expendi-
tures accounted for 46.7% of the total ex-
cess expenditures associated with severe
hypoglycemia. The mean annual total
medical expenditure for youth who expe-
rienced at least one severe hypoglycemia
episode was 1.4 times greater than for
Table 1—Characteristics of the study sample by DKA and severe hypoglycemia status (n 
7,556)
Characteristics
DKA
(n  1,126)
No DKA
(n  6,430)
Severe
hypoglycemia
(n  595)
No severe
hypoglycemia
(n  6,961)
Mean age (years) 12.05  0.13 12.81  0.05 12.92  0.19 12.68  0.05
Sex (% female) 51.42  1.49 47.01  0.62 51.76  2.05 47.32  0.60
Census regions
Midwest (%) 26.38  1.31 31.48  0.58 31.76  1.91 30.63  0.55
South (%) 50.53  1.49 41.43  0.61 44.20  2.04 42.67  0.59
West (%) 13.77  1.03 17.22  0.47 13.11  1.38 17.01  0.45
Urbanity of residence
(% urban) 81.17  1.17 80.26  0.50 77.14  1.72 80.68  0.47
Type of health plan
(% non-PPO) 23.53  1.26 24.79  0.54 23.19  1.73 24.72  0.52
Asthma (%) 6.04  0.71 3.75  0.24 5.88  0.97 3.94  0.23
Data are means  SE. Differences signiﬁcant at 0.05 by DKA or severe hypoglycemia status are shown
in bold.
Table 2—Per capita unadjusted mean annual medical expenditures (U.S. $) in 2007 for U.S.
youth with ITDM, by DKA and severe hypoglycemia status
Complication status
Expenditures (in U.S. $)
Total Outpatient Inpatient Drug
DKA
DKA 14,562  328 5,021  153 6,387  250 3,154  57
No DKA 8,370  153 3,797  63 871  105 3,703  50
Excess DKA 6,191  391* 1,224  164* 5,515  272* 548  123*
Severe hypoglycemia
Severe hypoglycemia 14,040  833 5,894  269 4,295  638 3,851  163
No severe hypoglycemia 8,887  135 3,815  59 1,471  93 3,601  45
Excess severe hypoglycemia 5,153  523* 2,079  217* 2,824  368* 250  163
Youth with zero expenses (%) 0.0 0.0 83.2 0.0
Data are means  SE. *P  0.05.
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episodes.
CONCLUSIONS — Ourstudyshowed
that the excess medical expenditures as-
sociated with DKA and severe hypoglyce-
mia were substantial among U.S. youth
with ITDM. However, both DKA and se-
vere hypoglycemia can be prevented or
incidencesreduced.Postersinschooland
family pediatricians’ ofﬁce settings and
providing guidelines for testing type 1 di-
abetes to pediatricians reduced the inci-
dence of DKA at diabetes diagnosis (23).
Behavioral therapy and parent trainings
have reduced postdiagnostic DKA hospi-
tal admissions (24). Thus, preventing
DKA or severe hypoglycemia by deliver-
ing appropriate and timely prevention
and patient care programs could avert
substantial healthcare expenditures.
We found that excess inpatient ex-
penditures attributed to DKA accounted
for 90% of the total excess medical ex-
pendituresattributedtoDKA.Thus,DKA
was treated primarily in hospital settings.
In comparison, total excess expenditures
associated with severe hypoglycemia
were fairly evenly divided between excess
inpatient and outpatient expenditures
(46.7 and 42.4%, respectively), indicat-
ing that severe hypoglycemia was treated
on both an out- and inpatient basis. Dif-
ferencesintreatmentsettingslikelyreﬂect
differences in the complications’ nature
and complexity.
Although more health care resources
were spent to care for youth who had
more than one episode of DKA or severe
hypoglycemiathanforthosewhohadone
episode, the average excess expenditure
per episode of DKA or severe hypoglyce-
mia was higher among youth who had
onlyoneepisode.Thishighercostislikely
attributed to expenditures associated
with the initial diagnosis.
One somewhat unexpected ﬁnding
was that expenditures for prescription
drugs were less among youth who expe-
rienced DKA than among those who did
not. One plausible explanation is that di-
abetic youth who use an inadequate
quantity of insulin might be at higher risk
of DKA. Alternately, DKA episodes
among youth with ITDM might have oc-
curredatdiabetesonsetwhentheywerestill
Table 3—Parameter estimates for medical expenditure models for youth in the U.S., 2007
Parameters Total# Outpatient#
Inpatient†
(ﬁrst part)
Inpatient
(second part)# Drug#
Constant 9.04  0.07* 8.26  0.07* 1.52  0.18* 8.66  0.16* 8.34  0.04*
Mean age (years) 0.003  0.003 0.01  0.004 0.06  0.01* 0.03  0.01* 0.005  0.002*
Sex: Girl ( 1) 0.04  0.03 0.10  0.03* 0.04  0.08 0.14  0.08 0.05  0.02*
Census regions
Midwest ( 1) 0.09  0.04* 0.02  0.05 0.26  0.14* 0.03  0.10 0.16  0.03*
South ( 1) 0.14  0.05* 0.13  0.05* 0.28  0.13* 0.04  0.12 0.16  0.03*
West ( 1) 0.08  0.06 0.12  0.06* 0.06  0.15 0.06  0.15 0.09  0.04*
Health plan
Non-PPO ( 1) 0.06  0.04 0.03  0.03 0.13  0.09 0.13  0.13 0.01  0.02
Urbanity of residence
Urban ( 1) 0.05  0.03 0.01  0.03 0.08  0.09 0.003  0.08 0.09  0.02*
Asthma ( 1) 0.49  0.09* 0.43  0.10* 0.55  0.17* 0.39  0.15* 0.30  0.07*
DKA ( 1) 0.53  0.03* 0.25  0.03* 3.17  0.08* 0.10  0.10 0.17  0.02*
Severe hypoglycemia ( 1) 0.36  0.05* 0.39  0.05* 0.72  0.12* 0.33  0.10* 0.08  0.04*
Log likelihood 76,328 70,036 2,443 12,939 69,426
Likelihood ratio 
2 1,960
Data are coefﬁcients  SE. *P  0.05. Boys, northeast region, rural residence, PPO health plan, and without asthma are treated as references. #Estimated using
generalized linear model with log link and gamma distribution. †Estimated using logistic regression model.
Table 4—Predicted mean annual medical expenditures (U.S. $) in 2007 for U.S. youth with
ITDM, by DKA and severe hypoglycemia status
Complication status Total
Components
Outpatient Inpatient Drug
DKA
DKA 14,236  322 4,886  148 6,228  214 3,135  56
No DKA 8,398  139 3,815  62 852  90 3,707  53
Excess DKA 5,837  353 1,071  161 5,376  233 572  75
Excess DKA (by number
of episodes)
1 episode 3,554  360 793  211 3,354  255 504  92
1 episode 8,455  529 1,388  228 7,694  390 650  87
Severe hypoglycemia
Severe hypoglycemia 12,850  127 5,644  266 3,166  452 3,896  151
No severe hypoglycemia 8,970  642 3,831  59 1,522  96 3,598  38
Excess severe hypoglycemia 3,880  649 1,813  264 1,644  421 298  157
Excess severe hypoglycemia
(by number of episodes)
1 episode 2,888  707 1,488  265 1,067  372 220  194
1 episode 5,929  1,369 2,478  522 3,035  963 458  243
Data are means  bootstrap SEs with 100 replications. Excess  the difference between mean medical
expenditures for youth with complications and those for youth with no complications. Covariates included
in the model are age, sex, census regions, urbanity of residence, health plan, and asthma. The amount of all
the excess expenditures was statistically signiﬁcant (P  0.05).
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thus required less exogenous insulin. Data
limitations prevented us from differentiat-
ing DKA episodes occurring at the onset of
diabetes from those among people with an
established diabetes diagnosis.
Our estimate of mean total medical
expenditure associated with DKA
($5,837) was less than half than that re-
ported for adults ($13,046 [2007 dol-
lars]) with type 1 diabetes (11). The
higher medical expenditures for adult di-
abetic patients with DKA could be attrib-
uted to disease severity. For instance, the
mean length of hospital stay among DKA
patients in our youth sample was 1.6
days, about one-fourth of adult hospital
stays(6.6days)(9).Thepresenceofother
comorbidities,suchascardiovasculardis-
eases and chronic diabetes complications
among adults, could contribute to the se-
verity of DKA in adults.
Our$3,880estimateofexcessannual
expenditures associated with severe hy-
poglycemia was slightly lower than an es-
timate of excess annual expenditures
associated with severe hypoglycemia
among insured employees with FFS and
capitated health plans in 1999–2000
($4,355 [2007 dollars]) (12) and a corre-
sponding estimate among patients under
managed care health plans in southern
U.S. states in 2002 ($4,319 [2007 dol-
lars]) (13). The higher medical expendi-
ture associated with severe hypoglycemia
among adults could be associated with
the severity of disease and chronic diabe-
tes complications.
Our study is subject to several limita-
tions. Our population was a convenience
sample of youth with insurance coverage
throughlargeemployer-sponsoredhealth
care programs. Those in our study were
likelytohaveabetteraccesstohealthcare
than those uninsured or covered under
Medicaid. Thus, our expenditure esti-
mates may not be applicable to all U.S.
youth with ITDM. Our estimates pertain
to youth enrolled in FFS plans without
uncommon chronic conditions. In sensi-
tivity analyses that included these condi-
tions, medical expenditures associated
with DKA or severe hypoglycemia
changed signiﬁcantly (results not re-
ported). Therefore, our results cannot be
extrapolated to this group of patients. In
addition, our estimates do not reﬂect
medical expenditures for youth insured
under capitated plans. Finally, because
we restricted our analysis to medical ex-
penditures from administrative claims
data, we did not capture the total cost of
DKA or severe hypoglycemia, including
the cost of medical care not paid for by
health insurance plans, other out-of-
pocket costs, the cost of care provided by
family members and by schools, and hu-
man capital losses.
To the best of our knowledge, this
was the ﬁrst study of medical expendi-
tures associated with acute diabetes com-
plications among a large sample of
privately insured U.S. youth with ITDM.
Themedicalexpendituresassociatedwith
treating both DKA and severe hypoglyce-
mia were substantial. Our estimates may
be useful in evaluating the economics of
pre- and postdiagnostic diabetes inter-
ventions that reduce DKA and severe hy-
poglycemia in U.S. youth.
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